The PPD™ clinical research business of Thermo Fisher Scientific, has announced a new research and development (R&D) partnership with the AstraZeneca BioVentureHub in Gothenburg, Sweden.
The partnership aims to leverage the combined expertise of Thermo Fisher and AstraZeneca to drive innovation and strengthen the life science ecosystem. A dedicated team from Thermo Fisher will co-locate with AstraZeneca scientists to work on collaborative R&D projects with a focus initially on chromatography, molecular genomics and proteomics.
The AstraZeneca BioVentureHub is part of a growing innovation ecosystem in Gothenburg that includes the GoCo Health Innovation City, future home of Thermo Fisher's bioanalytical laboratory that is under construction and expected to begin operations in March 2026. This state-of-the-art facility will serve pharmaceutical and biotech customers in Europe and across the globe, providing leading-edge bioanalytical laboratory capabilities to support all phases of pharmaceutical development to help customers deliver life-changing medicines to patients worldwide.
In addition to the new lab coming online in Sweden, the business operates a global network of GMP (good manufacturing practices), central, bioanalytical and vaccine science laboratories with operations based in Middleton, Wisconsin; Highland Heights, Kentucky; Richmond, Virginia; Athlone, Ireland; Brussels, Belgium; Singapore; and Suzhou, China.
